1,720,985 research outputs found
Valutazione del test cromogeno b-lactatm per l’identificazione rapida di Enterobatteri resistenti alle cefalosporine ad ampio spettro.
No full textCoesistenza di Klebsiella pneumoniae ed Escherichia coli kpc-3-produttori in una paziente in terapia intensiva.
No full textIn vitro activity of ceftaroline against a collection of hospital-acquired MRSA (ha-MRSA) and ha-MSSA italian isolates.
No full textCaratteristiche di antibiotico-resistenza in stipiti di Enterobatteri isolati da urinocolture di pazienti comunitari della provincia di Pavia
No full textDetection of an IncA/C plasmid encoding VIM-4 and CMY-4 β-lactamases in Klebsiella oxytoca and Citrobacter koseri from an inpatient in a cardiac rehabilitation unit
Full text linkA 62-year-old patient was transferred to the cardiac rehabilitation unit of the I.R.C.C.S. Fondazione S. Maugeri after undergoing a heart transplantation at the Acute Care Hospital I.R.C.C.S. S. Matteo of Pavia. On 1 August 2013 and during hospitalization in the rehabilitation unit, Klebsiella oxytoca and Citrobacter koseri clinical isolates were simultaneously recovered from the patient's preputial swab. Both the K. oxytoca and C. koseri strains were carbapenem- resistant by MicroScan System (Beckman Coulter). Carbapenem-resistant K. pneumoniae had previously been reported in the same rehabilitation facility. The aim of the study was to identify the carbapenem resistance mechanisms among the enterobacterial species recovered. Phenotypic screening tests useful to detect the β-lactamases/carbapenemases were performed. Carbapenem MICs were obtained by Etest. AmpC and MBL encoding genes were identified by PCR and sequencing. Conjugation assays and plasmid characterization were performed. Both of the K. oxytoca and C. koseri isolates were multi drug resistant, showing resistance to amoxicillin-clavulanic acid, three generation cephalosporins, ertapenem (K. oxytoca MIC, >32 mg/L; C. koseri MIC, 4 mg/L), imipenem (K. oxytoca MIC, 4 mg/L; C. koseri MIC, 12 mg/L), thrimethoprim sulphamethoxazole and gentamicin. Susceptibility was retained to fluoroquinolones, colistin and tigecycline. Molecular characterization confirmed the co-presence of blaCMY-4 and blaVIM-4 determinants in a 150 Kb transferable plasmid of IncA/C group. This case is the first detection in Italy of the K. oxytoca and C. koseri clinical isolates co-producing the CMY-4 and VIM-4 enzymes
Valutazione dell’attività in vitro di ceftaroline nei confronti di ceppi di Staphylococcus aureus MRSA e MSSA isolati in ambito ospedaliero ed ambulatoriale del nord Italia
No full textDiffusione di due cloni di Escherichia coli kpc-produttori in reparti diversi di un ospedale per acuti del nord Italia.
No full textClinical isolation of an Enterobacter cloacae strain producing the novel plasmid-borne AmpC ACT-24 variant
No full textKlebsiella oxytoca e Citrobacter koseri ESbL- e VIM-produttori in un paziente in riabilitazione cardiologica: caso clinico
No full text
- …
